Developing Prioritization Criteria to Identify Target Drugs for CalRx, the California Generic Drugs Initiative

The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance 

A Conceptual Framework for Life-Cycle Health Technology Assessment

Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists

Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia

Drug Prices and Value of Oncology Drugs in Italy

Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a “Shared Savings” Approach to Cost Offsets

International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects

Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance

Managed Entry Agreements: Policy Analysis From the European Perspective

Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis

Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System

To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland

Defining and Managing High-Priced Cures: Healthcare Payers’ Opinions

Implications of Nonmarginal Budgetary Impacts in Health Technology Assessment: A Conceptual Model

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value

Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures

Paying for Cures: Perspectives on Solutions to the “Affordability Issue”

Affordability of New Technologies: The Next Frontier

Toward a Hedonic Value Framework in Health Care

Analysis of Medicine Prices in New Zealand and 16 European Countries

Patient Access to New Cancer Drugs in the United States and Australia

The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Contribute to Value in Health

  • Submit a manuscript/revision
  • Become a peer reviewer
  • Check manuscript status

Scholar One

 

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×